长链非编码RNA EXOC7在非酒精性脂肪性肝病中的表达及临床意义

张丽云; 邓家琦; 张双; 邓华江; 李晓红

doi:10.3969/j.issn.1001-5256.2020.02.032

长链非编码RNA EXOC7在非酒精性脂肪性肝病中的表达及临床意义

DOI: 10.3969/j.issn.1001-5256.2020.02.032

1. 西南医科大学附属医院健康管理中心
2. 西南医科大学附属医院超声医学科
3. 西南医科大学附属医院老年病科
4. 西南医科大学附属医院神经外科

基金项目:

泸州市科技创新苗子培育计划项目(2017-R-67)；西南医科大学青年基金(2018-ZRQN-077)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 1106
- HTML全文浏览量: 71
- PDF下载量: 192
- 被引次数: 0
出版历程
- 收稿日期: 2019-10-10
- 出版日期: 2020-02-20

Expression and significance of the long non-coding RNA EXOC7 in nonalcoholic fatty liver disease

Health Management Center,The Affiliated Hospital of Southwest Medical University

Research funding:

摘要

摘要:
目的观察非酒精性脂肪性肝病（NAFLD）患者血清及肝穿刺组织中长链非编码RNA（lncRNA） EXOC7的表达及临床意义。方法选取2013年1月1日-2018年12月31日于西南医科大学附属医院住院行肝穿刺并经影像学及组织病理学诊断为NAFLD的患者120例,其中非酒精性单纯性脂肪肝（NAFL） 47例,非酒精性脂肪性肝炎（NASH） 73例。另选取同期体检的50例无脂肪变性和脂肪性肝炎的其他肝病患者作为对照组。采用Real-time PCR法检测lncRNA EXOC7在肝组织及血清中的表达。计量资料两组间比较采用t检验;多组间比较采用方差分析,进一步两两比较采用SNK-q检验。计数资料两组间比较采用χ2检验。采用Pearson相关分析lncRNA EXOC7表达与临床各生化指标的关系。绘制受试者工作特征曲线（ROC曲线）并分析lncRNA EXOC7的临床诊断价值。结果与对照组相比,NAFL和NASH患者的组织及血清中lncRNA EXOC7表达显著增高（P值均<0. 05）,且其表达水平随着肝脏脂肪变性及炎症程度的加重而提升（F=19. 96,P <0. 05）。相...
- 非酒精性脂肪性肝病 /
- RNA,长链非编码 /
- 诊断
Abstract:
Objective To investigate the expression of the long non-coding RNA( lncRNA) EXOC7 in serum and liver biopsy tissue of patients with nonalcoholic fatty liver( NAFLD) and its clinical significance. Methods A total of 120 patients who underwent liver biopsy in The Affiliated Hospital of Southwest Medical University from January 1,2013 to December 31,2018 and were diagnosed with NAFLD based on imaging and histopathology were enrolled,among whom 47 had nonalcoholic fatty liver( NAFL) and 73 had nonalcoholic steatohepatitis( NASH). A total of 50 liver disease patients without steatosis or steatohepatitis were enrolled as control group. Real-time PCR was used to measure the expression of lncRNA EXOC7 in liver tissue and serum. The t-test was used for comparison of continuous data between two groups; an analysis of variance was used for comparison between multiple groups,and the SNK-q test was used for further comparison between two groups. A chi-square test was used for comparison of categorical data between groups. A Pearson correlation analysis was used to investigate the correlation between lncRNA EXOC7 and biochemical parameters. The receiver operating characteristic( ROC) curve was plotted to investigate the diagnostic value of lncRNA EXOC7. Results Compared with the control group,the patients with NAFL or NASH had significant increases in the expression of lncRNA EXOC7 in liver tissue and serum( all P < 0. 05),and the level of such expression increased with the aggravation of hepatic steatosis and inflammation( F = 19. 96,P < 0. 05). The correlation analysis showed that the expression of lncRNA EXOC7 was positively correlated with total triglyceride and low-density lipoprotein cholesterol( r = 0. 785 and r = 0. 847,both P < 0. 001) and was negatively correlated with high-density lipoprotein cholesterol and insulin sensitivity index( r =-0. 726 and-0. 709,both P < 0. 001). LncRNA EXOC7 had an area under the ROC curve of 0. 812( 95% confidence interval: 0. 599-0. 915,P < 0. 001),a sensitivity of85. 42%,and a specificity of 81. 17% in the diagnosis of NAFLD. Conclusion LncRNA EXOC7 is highly expressed in patients with NAFLD,and the expression of lncRNA EXOC7 increases with the aggravation of hepatic steatosis and inflammation,suggesting that lncRNA EXOC7 may be a potential new target for the prevention and treatment of NAFLD.
- non-alcoholic fatty liver disease /
- RNA,long noncoding /
- diagnosis

HTML全文

参考文献(23)

[1] HARTLEY A,SANTOS FERREIRA DL,ANDERSON EL,et al.Metabolic profiling of adolescent non-alcoholic fatty liver disease[J]. Wellcome Open Res,2019,3:166.

[2] ABU DAYYEH BK,BAZERBACHI F,GRAUPERA I,et al. Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease[J]. J Hepatol,2019,71(6):1246-1248.

[3] CHAKRABORTY A,CHOUDHURY A,SAHA A. Development of non-alcoholic fatty liver disease(NAFLD)in young obese tribal subjects of Tripura:Link between low 25(OH)vitamin-D levels and immune modulators[J]. J Assoc Physicians India,2019,67(8):52-56.

[4] FEKRY B,RIBAS-LATRE A,BAUMGARTNER C,et al. HNF4α-deficient fatty liver provides a permissive environment for sex-independent hepatocellular carcinoma[J]. Cancer Res,2019,79(22):5860-5873.

[5] WANG T,PAN W,HU J,et al. Circular RNAs in metabolic diseases[J]. Adv Exp Med Biol,2018,1087:275-285.

[6] MA TT,HUANG C,NI Y,et al. ATP citrate lyase and lncRNA NONMMUT010685 play crucial role in nonalcoholic fatty liver disease based on analysis of microarray data[J]. Cell Physiol Biochem,2018,51(2):871-885.

[7] SALUJA M,KUMAR K,SWAMI YK,et al. Association between non-alcoholic fatty liver disease and left ventricular diastolic dysfunction in patients of type 2 diabetes[J]. J Assoc Physicians India,2019,67(8):20-24.

[8] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of non-alcoholic fatty liver disease:Practice Guideline by the American Association for the Study of Liver Diseases,American College of Gastroenterology,and the American Gastroenterological Association[J]. Hepatology,2012,55(6):2005-2023.

[9] LEE J,PARK JS,ROH YS. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease[J]. Arch Pharm Res,2019,42(11):935-946.

[10] YANG S,KWAK S,LEE JH,et al. Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population[J]. PLo S One,2019,14(11):e0224626.

[11] LIU T,LUO X,LI ZH,et al. Zinc-α2-glycoprotein 1 attenuates non-alcoholic fatty liver disease by negatively regulating tumour necrosis factor-α[J]. World J Gastroenterol,2019,25(36):5451-5468.

[12] RHEE EJ. Nonalcoholic fatty liver disease and diabetes:An epidemiological perspective[J]. Endocrinol Metab(Seoul),2019,34(3):226-233.

[13] WU J,PENG X,QIAO M,et al. Genome-wide analysis of long noncoding RNA and mRNA profiles in PRRSV-infected porcine alveolar macrophages[J]. Genomics,2019.[Epub ahead of print]

[14] BERGAD-PIJUAN J,PULIDO-QUETGLAS C,VANCURA A,et al. CASPR,an analysis pipeline for single and paired guide RNA CRISPR screens,reveals optimal target selection for long noncoding RNAs[J]. Bioinformatics,2019.[Epub ahead of print]

[15] WU H,SONG X,LING Y,et al. Comprehensive bioinformatics analysis of critical lncRNAs,mRNAs and miRNAs in non-alcoholic fatty liver disease[J]. Mol Med Rep,2019,19(4):2649-2659.

[16] CHEN X,TAN XR,LI SJ,et al. LncRNA NEAT1 promotes hepatic lipid accumulation via regulating miR-146a-5p/ROCK1in nonalcoholic fatty liver disease[J]. Life Sci,2019,235:116829.

[17] WANG B,LI X,HU W,et al. Silencing of lncRNA SNHG20delays the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma via regulating liver Kupffer cells polarization[J]. IUBMB Life,2019,71(12):1952-1961.

[18] CHEN Y,CHEN X,GAO J,et al. Long noncoding RNA FLRL2alleviated nonalcoholic fatty liver disease through Arntl-Sirt1pathway[J]. FASEB J,2019,33(10):11411-11419.

[19] SUN Y,SONG Y,LIU C,et al. LncRNA NEAT1-MicroRNA-140 axis exacerbates nonalcoholic fatty liver through interrupting AMPK/SREBP-1 signaling[J]. Biochem Biophys Res Commun,2019,516(2):584-590.

[20] LIU J,TANG T,WANG GD,et al. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγaxis in non-alcoholic fatty liver disease[J]. Biosci Rep,2019,39(7):BSR20181722.

[21] SHEN X,GUO H,XU J,et al. Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease[J]. J Cell Physiol,2019,234(10):18169-18179.

[22] ZHANG B,LI H,LI D,et al. Long noncoding RNA Mirt2 upregulates USP10 expression to suppress hepatic steatosis by sponging miR-34a-5p[J]. Gene,2019,700:139-148.

[23] HUANG P,HUANG FZ,LIU HZ,et al. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6[J]. Metabolism,2019,94:1-8.

施引文献

资源附件(0)

访问统计